Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of APL-101 vs PLB-1001 (Vebreltinib) in Healthy Subjects
NCT05367388Phase 1Unknown
- Sponsor
- Apollomics, Inc.
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vebreltinib in non-small cell lung cancer (NSCLC) and glioblastoma (GBM) (2 arms), sponsored by Apollomics, Inc. Primary endpoints: Area under the plasma concentration versus time curve and Maximum observed plasma concentration. Status: unknown.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05367388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367388.